Syngene International Limited
Healthcare›Healthcare›Healthcare Services›Healthcare Research, Analytics & Technology
Key metrics
Price as of 2026-07-20
Stock price
₹417.60
Market cap
16,825 Cr
Stock P/E
68.7
P/B
3.48
Dividend yield
0.3%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 808 Cr | 1,718 Cr | 2,572 Cr | 3,489 Cr | 790 Cr | 1,681 Cr | 944 Cr | 1,018 Cr | 875 Cr | 911 Cr | 917 Cr | 1,037 Cr |
| Operating expenses (approx.) | 573 Cr | 1,214 Cr | 1,811 Cr | 2,395 Cr | 570 Cr | 1,200 Cr | 642 Cr | 656 Cr | 650 Cr | 696 Cr | 763 Cr | 717 Cr |
| EBITDA | 236 Cr | 504 Cr | 761 Cr | 1,094 Cr | 220 Cr | 481 Cr | 302 Cr | 363 Cr | 224 Cr | 215 Cr | 154 Cr | 320 Cr |
| OPM % | 29.1% | 29.3% | 29.6% | 31.4% | 27.8% | 28.6% | 32.0% | 35.6% | 25.6% | 23.6% | 16.8% | 30.8% |
| Other income | 24 Cr | 45 Cr | 75 Cr | 91 Cr | 18 Cr | 35 Cr | 18 Cr | 19 Cr | 18 Cr | 15 Cr | 15 Cr | 22 Cr |
| Interest | 11 Cr | 24 Cr | 34 Cr | 47 Cr | 12 Cr | 25 Cr | 12 Cr | 16 Cr | 12 Cr | 13 Cr | 12 Cr | 12 Cr |
| Depreciation | 102 Cr | 207 Cr | 315 Cr | 426 Cr | 107 Cr | 218 Cr | 109 Cr | 106 Cr | 111 Cr | 117 Cr | 114 Cr | 112 Cr |
| Profit before tax | 123 Cr | 274 Cr | 412 Cr | 621 Cr | 101 Cr | 239 Cr | 181 Cr | 241 Cr | 101 Cr | 85 Cr | 28 Cr | 196 Cr |
| Tax % | 24.0% | 23.3% | 22.0% | 17.8% | 25.3% | 23.8% | 27.5% | 23.8% | 14.4% | 21.2% | 47.2% | 24.5% |
| Net profit | 93 Cr | 210 Cr | 321 Cr | 510 Cr | 76 Cr | 182 Cr | 131 Cr | 183 Cr | 87 Cr | 67 Cr | 15 Cr | 148 Cr |
| EPS (₹) | ₹2.33 | ₹5.23 | ₹8.01 | ₹12.71 | ₹1.89 | ₹4.53 | ₹3.27 | ₹4.56 | ₹2.16 | ₹1.67 | ₹0.37 | ₹3.68 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,826 Cr | 2,012 Cr | 2,184 Cr | 2,604 Cr | 3,193 Cr | 3,489 Cr | 3,642 Cr | 3,739 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,214 Cr | 1,241 Cr | 1,413 Cr | 1,786 Cr | 2,259 Cr | 2,485 Cr | 2,497 Cr | 2,826 Cr | Sign in for TTM |
| EBITDA | 612 Cr | 771 Cr | 771 Cr | 818 Cr | 934 Cr | 1,003 Cr | 1,146 Cr | 913 Cr | Sign in for TTM |
| OPM % | 33.5% | 38.3% | 35.3% | 31.4% | 29.3% | 28.8% | 31.5% | 24.4% | Sign in for TTM |
| Other income | 75 Cr | 82 Cr | 65 Cr | 53 Cr | 71 Cr | 91 Cr | 72 Cr | 71 Cr | Sign in for TTM |
| Interest | 32 Cr | 35 Cr | 28 Cr | 24 Cr | 45 Cr | 47 Cr | 53 Cr | 49 Cr | Sign in for TTM |
| Depreciation | 164 Cr | 219 Cr | 275 Cr | 310 Cr | 367 Cr | 426 Cr | 433 Cr | 453 Cr | Sign in for TTM |
| Profit before tax | 415 Cr | 517 Cr | 469 Cr | 484 Cr | 594 Cr | 621 Cr | 660 Cr | 411 Cr | Sign in for TTM |
| Tax % | 20.2% | 20.3% | 13.7% | 18.3% | 21.8% | 17.8% | 24.8% | 22.9% | Sign in for TTM |
| Net profit | 332 Cr | 412 Cr | 405 Cr | 396 Cr | 464 Cr | 510 Cr | 496 Cr | 317 Cr | Sign in for TTM |
| EPS (₹) | ₹16.77 | ₹10.38 | ₹10.18 | ₹9.94 | ₹11.59 | ₹12.71 | ₹12.35 | ₹7.87 | Sign in for TTM |
| Dividend payout % | — | — | — | 0.0% | 8.6% | 9.9% | 10.1% | 15.9% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 200 Cr | 400 Cr | 400 Cr | 401 Cr | 401 Cr | 402 Cr | 403 Cr | 403 Cr |
| Reserves | 1,768 Cr | 0.0000 Cr | 0.0000 Cr | 2,897 Cr | 3,217 Cr | 3,856 Cr | 4,324 Cr | 4,436 Cr |
| Borrowings | 552 Cr | 309 Cr | 772 Cr | 790 Cr | 575 Cr | 142 Cr | 120 Cr | 9 Cr |
| Other liabilities | 1,183 Cr | 1,679 Cr | 1,287 Cr | 1,479 Cr | 1,638 Cr | 1,752 Cr | 1,950 Cr | 2,206 Cr |
| Total liabilities | 3,702 Cr | 4,162 Cr | 4,878 Cr | 5,561 Cr | 5,831 Cr | 6,152 Cr | 6,796 Cr | 7,055 Cr |
| Fixed assets (net) | 1,323 Cr | 1,877 Cr | 2,032 Cr | 2,123 Cr | 2,383 Cr | 2,378 Cr | 2,323 Cr | 2,545 Cr |
| CWIP | 274 Cr | 234 Cr | 237 Cr | 346 Cr | 177 Cr | 837 Cr | 1,261 Cr | 1,040 Cr |
| Investments | 716 Cr | 817 Cr | 702 Cr | 1,034 Cr | 919 Cr | 548 Cr | 647 Cr | 741 Cr |
| Other assets | 1,763 Cr | 1,611 Cr | 1,801 Cr | 2,204 Cr | 2,425 Cr | 1,959 Cr | 2,287 Cr | 2,143 Cr |
| Total assets | 3,702 Cr | 4,162 Cr | 4,878 Cr | 5,561 Cr | 5,831 Cr | 6,152 Cr | 6,796 Cr | 7,055 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 581 Cr | 824 Cr | 1,042 Cr | 1,168 Cr | 915 Cr |
| Cash from investing | — | — | — | -611 Cr | -656 Cr | -496 Cr | -745 Cr | -860 Cr |
| Cash from financing | — | — | — | -31 Cr | -342 Cr | -551 Cr | -142 Cr | -215 Cr |
| Net cash flow | — | — | — | -61 Cr | -172 Cr | -4 Cr | 281 Cr | -138 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 105 Cr | 317 Cr | 550 Cr | 407 Cr | 571 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 22.7% | 137.9% | 124.2% | 15.4% | 13.5% | 13.1% | 14.7% | 9.5% |
| ROE % | 16.8% | 0.0% | 0.0% | 0.0% | 0.0% | 12.0% | 0.0% | 0.0% |
| Debtor days | 68 | 72 | 57 | 71 | 60 | 46 | — | — |
| Inventory days | 31 | 18 | 39 | 85 | 134 | 100 | 61 | 56 |
| Days payable | 161 | 157 | 158 | 111 | 104 | 107 | — | — |
| Cash conversion cycle | -62 | -67 | -62 | 45 | 91 | 39 | 61 | 56 |
| Debt / equity | 0.28 | 0.14 | 0.27 | 0.24 | 0.16 | 0.03 | 0.03 | 0.0019 |
| Current ratio | 1.56 | 1.05 | 1.59 | 1.79 | 2.04 | 1.71 | 1.64 | 1.38 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.52 | 0.06 | -0.22 | -0.24 |
Compare with peers
Loading peers…